Actualités sur Medikament

Suivre
Abonner Medikament
Filtre
  • 16.07.2025 – 08:00

    Schweizerischer Nationalfonds / Fonds national suisse

    Tackling antibiotic resistance by capturing bacteria

    Bern (ots) - Rapidly identifying certain bacteria allows antibiotic treatments to be optimised. A team from the University of Zurich, supported by the SNSF, has developed molecules to detect and capture certain species. The discovery of antibiotics revolutionised medicine in the 20th century, saving countless lives. However, the emergence of resistant bacteria has quickly become a new challenge. One key factor in tackling ...

  • 17.06.2025 – 13:31

    Isomorphic Labs

    Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence

    London and Boston (ots/PRNewswire) - Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly ...

  • 17.06.2025 – 09:02

    MedHub; Terumo

    MedHub-AI and Terumo partner to market AI-based FFR in Japan

    Tel Aviv, Israel (ots/PRNewswire) - MedHub-AI, pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical ...

  • 16.06.2025 – 13:40

    Innovative Molecules GmbH

    Innovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250

    Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...

  • 02.06.2025 – 11:39

    BIAL SA

    BIAL Announces Oral Presentation at GBA1 Meeting 2025

    Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...

  • 02.06.2025 – 09:59

    Grünenthal Group

    Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

    Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...